These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 21301456)

  • 1. Editorial: toll-like receptor expression in irritable bowel syndrome: on the alert for a microbial threat?
    Barbara G
    Am J Gastroenterol; 2011 Feb; 106(2):337-9. PubMed ID: 21301456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential expression of toll-like receptors in patients with irritable bowel syndrome.
    Brint EK; MacSharry J; Fanning A; Shanahan F; Quigley EM
    Am J Gastroenterol; 2011 Feb; 106(2):329-36. PubMed ID: 21102570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered peripheral toll-like receptor responses in the irritable bowel syndrome.
    McKernan DP; Gaszner G; Quigley EM; Cryan JF; Dinan TG
    Aliment Pharmacol Ther; 2011 May; 33(9):1045-52. PubMed ID: 21453321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of irritable bowel syndrome--review regarding associated infection and immune activation.
    Ishihara S; Tada Y; Fukuba N; Oka A; Kusunoki R; Mishima Y; Oshima N; Moriyama I; Yuki T; Kawashima K; Kinoshita Y
    Digestion; 2013; 87(3):204-11. PubMed ID: 23712295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.
    Barbara G; Zecchi L; Barbaro R; Cremon C; Bellacosa L; Marcellini M; De Giorgio R; Corinaldesi R; Stanghellini V
    J Clin Gastroenterol; 2012 Oct; 46 Suppl():S52-5. PubMed ID: 22955358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucosal barrier defects in irritable bowel syndrome. Who left the door open?
    Barbara G
    Am J Gastroenterol; 2006 Jun; 101(6):1295-8. PubMed ID: 16771952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The putative role of the intestinal microbiota in the irritable bowel syndrome.
    Collins SM; Denou E; Verdu EF; Bercik P
    Dig Liver Dis; 2009 Dec; 41(12):850-3. PubMed ID: 19740713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome.
    Coëffier M; Gloro R; Boukhettala N; Aziz M; Lecleire S; Vandaele N; Antonietti M; Savoye G; Bôle-Feysot C; Déchelotte P; Reimund JM; Ducrotté P
    Am J Gastroenterol; 2010 May; 105(5):1181-8. PubMed ID: 19997094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators.
    Piche T; Barbara G; Aubert P; Bruley des Varannes S; Dainese R; Nano JL; Cremon C; Stanghellini V; De Giorgio R; Galmiche JP; Neunlist M
    Gut; 2009 Feb; 58(2):196-201. PubMed ID: 18824556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype.
    Belmonte L; Beutheu Youmba S; Bertiaux-Vandaële N; Antonietti M; Lecleire S; Zalar A; Gourcerol G; Leroi AM; Déchelotte P; Coëffier M; Ducrotté P
    PLoS One; 2012; 7(8):e42777. PubMed ID: 23028414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Gargano L; Cogliandro R; Pallotti F; Corinaldesi R
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S214-7. PubMed ID: 18685517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased mucosal expression of Toll-like receptor (TLR)2 and TLR4 in coeliac disease.
    Szebeni B; Veres G; Dezsofi A; Rusai K; Vannay A; Bokodi G; Vásárhelyi B; Korponay-Szabó IR; Tulassay T; Arató A
    J Pediatr Gastroenterol Nutr; 2007 Aug; 45(2):187-93. PubMed ID: 17667714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial: Can gluten contribute to irritable bowel syndrome?
    Verdu EF
    Am J Gastroenterol; 2011 Mar; 106(3):516-8. PubMed ID: 21378766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Postinfectious irritable bowel syndrome].
    Döbrönte Z; Lakner L; Sarang K
    Orv Hetil; 2006 Oct; 147(43):2077-80. PubMed ID: 17297754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.
    Barbara G; Stanghellini V; Cremon C; De Giorgio R; Fronzoni L; Serra M; Corinaldesi R
    Dig Dis; 2009; 27 Suppl 1():115-21. PubMed ID: 20203507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets.
    Kraneveld AD; Rijnierse A; Nijkamp FP; Garssen J
    Eur J Pharmacol; 2008 May; 585(2-3):361-74. PubMed ID: 18417115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Microbiota and irritable bowel syndrome].
    Ducrotté P
    Gastroenterol Clin Biol; 2010 Sep; 34 Suppl 1():S52-6. PubMed ID: 20889005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms?
    Hughes PA; Zola H; Penttila IA; Blackshaw LA; Andrews JM; Krumbiegel D
    Am J Gastroenterol; 2013 Jul; 108(7):1066-74. PubMed ID: 23649183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role.
    Bolino CM; Bercik P
    Infect Dis Clin North Am; 2010 Dec; 24(4):961-75, ix. PubMed ID: 20937460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.